| --- | --- | |------------------------|-------| | | | | | | | | | | | | | | | | Corporate Presentation | | | | | | | | | | | | March 2021 | | | (NYSE AMER: MTNB) | 1 | Forward-Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that ...

| --- | --- | --- | |--------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation December 2020 | | | Forward-Looking Statement MTNB This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predi ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q3 2020 Results Conference Call November 6, 2020 8:30 AM ET Company Participants Peter Vozzo - IR Jerry Jabbour - CEO Keith Kucinski - CFO Dr. James Ferguson - Chief Medical Officer Conference Call Participants Bert Hazlett - BTIG Yasmeen Rahimi - Piper Sandler Operator Greetings. Welcome to Matinas BioPharma Third Quarter 2020 Results Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal pre ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) 908-443-1860 (Registrant's telephone num ...

MAT9001 - Potential Best-in-Class Omega-3 Drug - MAT9001 aims to target the multi-billion dollar market for severe hypertriglyceridemia (SHTG) [8, 25] - Head-to-head data showed MAT9001's superiority in triglyceride lowering and EPA levels compared to Vascepa® [8] - Approximately 3.5 to 4 million adults in the United States have severe hypertriglyceridemia (SHTG, ≥500 mg/dL) [28] - The ENHANCE-IT study, a head-to-head comparison of MAT9001 vs Vascepa®, is fully enrolled as of August 2020, with top-line data expected in Q1 2021 [14] - MAT9001 demonstrated a median triglyceride reduction of -33% versus -32.5% for Vascepa® in a head-to-head study [36] MAT2203 - Oral Amphotericin B for Invasive Fungal Infections - The global invasive fungal infection market is valued at approximately $6 billion in 2018 [65] - Global Amphotericin B sales were approximately $800 million in 2018 [65] - EnACT study is a Phase 2 study in HIV patients with Cryptococcal Meningitis [9, 73] LNC Platform - Matinas' LNC Platform enables flexible, safe, targeted delivery of potent medicines [10, 79] - The company has feasibility evaluations with three Big Pharma companies across multiple compounds [10] - $50M+ equity financing in January 2020 extends cash runway to early 2023 [16]

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Peter Vozzo - IR Jerry Jabbour - CEO Terri Matkovits - Chief Development Officer Conference Call Participants Michael Okunewitch - Maxim Group Gregg Gilbert - Truist Operator Welcome to the Matinas BioPharma Second Quarter 2020 Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a rem ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 (Address of principal executive offices) (Zip Code) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTIO ...

| --- | --- | --- | |----------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation June 2020 | | | Forward-Looking Statement MTNB This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Peter Vozzo - Investor Relations Jerry Jabbour - Chief Executive Officer Terry Ferguson - Chief Medical Officer Terri Matkovits - Chief Development Officer Conference Call Participants Bert Hazlett - BTIG Ed Tenthoff - Piper Sandler Jason McCarthy - Maxim Group Greg Fraser - SunTrust Chad Messer - Needham & Company Operator Welcome to the Matinas BioPharma First Quarter 2020 Results Con ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other ...